Vanda Pharmaceuticals Inc (VNDA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vanda Pharmaceuticals Inc (VNDA) has a cash flow conversion efficiency ratio of -0.090x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-29.42 Million) by net assets ($327.19 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Vanda Pharmaceuticals Inc (VNDA) total market value for the company's overall valuation and market capitalisation.
Vanda Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how Vanda Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Vanda Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vanda Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Explore Vanda Pharmaceuticals Inc cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Liaoning SG Automotive Group Co Ltd
SHG:600303
|
-0.081x |
|
Repay Holdings Corp
NASDAQ:RPAY
|
0.035x |
|
Mehadrin
TA:MEDN
|
-0.080x |
|
ASOS PLC UN.ADR 1 LS-035
F:DYQ0
|
N/A |
|
Bali Towerindo Sentra Tbk
JK:BALI
|
0.048x |
|
Global Indemnity PLC
NYSE:GBLI
|
0.010x |
|
Nalwa Sons Investments Limited
NSE:NSIL
|
0.003x |
|
Silver Tiger Metals Inc
V:SLVR
|
-0.008x |
Annual Cash Flow Conversion Efficiency for Vanda Pharmaceuticals Inc (2004–2025)
The table below shows the annual cash flow conversion efficiency of Vanda Pharmaceuticals Inc from 2004 to 2025. View current stock price of Vanda Pharmaceuticals Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $327.19 Million | $-109.44 Million | -0.334x | -1043.24% |
| 2024-12-31 | $538.55 Million | $-15.76 Million | -0.029x | -224.55% |
| 2023-12-31 | $544.91 Million | $12.80 Million | 0.023x | -61.28% |
| 2022-12-31 | $527.20 Million | $31.98 Million | 0.061x | -52.30% |
| 2021-12-31 | $504.93 Million | $64.21 Million | 0.127x | +11.34% |
| 2020-12-31 | $453.27 Million | $51.77 Million | 0.114x | +2.16% |
| 2019-12-31 | $410.94 Million | $45.95 Million | 0.112x | +2.70% |
| 2018-12-31 | $275.42 Million | $29.99 Million | 0.109x | +821.36% |
| 2017-12-31 | $131.39 Million | $-1.98 Million | -0.015x | +75.54% |
| 2016-12-31 | $131.33 Million | $-8.10 Million | -0.062x | -165.93% |
| 2015-12-31 | $133.03 Million | $12.45 Million | 0.094x | +118.45% |
| 2014-12-31 | $160.82 Million | $-81.55 Million | -0.507x | +43.48% |
| 2013-12-31 | $44.12 Million | $-39.59 Million | -0.897x | +80.21% |
| 2012-12-31 | $9.90 Million | $-44.92 Million | -4.535x | -434.31% |
| 2011-12-31 | $33.47 Million | $-28.41 Million | -0.849x | -193.84% |
| 2010-12-31 | $37.73 Million | $-10.90 Million | -0.289x | -103.93% |
| 2009-12-31 | $23.03 Million | $169.34 Million | 7.353x | +836.30% |
| 2008-12-31 | $46.02 Million | $-45.96 Million | -0.999x | -61.91% |
| 2007-12-31 | $83.73 Million | $-51.64 Million | -0.617x | +68.03% |
| 2006-12-31 | $26.76 Million | $-51.62 Million | -1.929x | -233.96% |
| 2005-12-31 | $30.66 Million | $-17.71 Million | -0.578x | -6.91% |
| 2004-12-31 | $15.94 Million | $-8.61 Million | -0.540x | -- |
About Vanda Pharmaceuticals Inc
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nightt… Read more